Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Clinical trial NCT05400122 · SUSPENDED

Trial details

NCT number: NCT05400122
Sponsor: David Wald
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Colorectal Cancer Hematologic Malignancy Rectum Cancer Acute Myeloid Leukemia Myelodysplastic Syndromes Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Chronic Lymphocytic Leukemia Hodgkin Lymphoma Non Hodgkin Lymphoma Myeloproliferative Syndrome Plasma Cell Myeloma

Start date: 2022-09-09
Primary completion: 2026-12-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.